Breaking News

Advinus Earns Takeda Milestone

By Kristin Brooks | January 7, 2014

R&D collaboration completes first successful year

Advinus Therapeutics Ltd., the TATA promoted Pharmaceutical R&D Co., has received a $3 million milestone for the first successful year in its R&D collaboration with Takeda Pharmaceutical Co.
 
In October 2012, the companies entered a multi-year, multi-project drug discovery collaboration. Advinus is responsible for carrying out all research required to identify candidate molecules for clinical development in several therapeutic areas, and Takeda is responsible for development and commercialization.
 
"Achievement of the rather challenging first year milestone can be attributed to the truly collaborative nature of our relationship with Takeda as well as Advinus' ability to solve complex problems with efficiency and speed,” said Kasim Mookhtiar, chief scientific officer of Advinus.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.